Sub-Investigator of the following clinical trials:

– Modulation of neuronal connectivity along the optical pathways in glaucoma patients through treatment with citicoline in oral solution: multimodal morpho-functional study

– Efficacy and safety assessment of T4030 eye drops versus Ganfort® UD in ocular hypertensive or glaucomatous patients. LT4030-301

– A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension TRITON 1698-301-007

– Basic human research study of novel glaucoma endpoints and identification of optimal patient populations forneuroprotection trials CBASICHR0031

– Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis

– Phase III study, multinational, multicentre, masked for the investigator, randomized, with active control, to compare the efficacy and safety of DE-130A compared to Xalatan® in

patients with open-angle glaucoma or ocular hypertension over the course of 3 months, followed by a 12-month follow-up with open-label DE-130A treatment. CATIOPROST – 0130A01SA

– 24-hour efficacy and tolerability of the fixed combination tafluprost -timolol without preservatives in glaucomatous or ocular hypertensive patients already being treated with latanoprost preserved with BAK. Open-label prospective study lasting 3 months. HERO

– Evaluation of the agreement in the diagnosis of glaucoma campimetric progression